Page 6,905«..1020..6,9046,9056,9066,907..6,9106,920..»

FDA Approves New Erectile Dysfunction Drug Stendra

Posted: Published on April 29th, 2012

Stendra Works Like Cialis, Levitra, Staxyn, Viagra April 27, 2012 -- The FDA has approved Stendra (avanafil) for men with erectile dysfunction (ED). Stendra, from Vivus Inc., is in the same drug class as the four oral ED drugs now on the U.S. market: Cialis, Levitra, Staxyn (an orally dissolving version of Levitra), and Viagra. An estimated 30 million U.S. men have ED, according to the FDA. "This approval expands the available treatment options to men experiencing erectile dysfunction, and enables patients, in consultation with their doctor, to choose the most appropriate treatment for their needs," Victoria Kusiak, MD, deputy director of the Office of Drug Evaluation III in the FDA's Center for Drug Evaluation and Research, states in a news release. In some participants in clinical trials, the drug was effective in as little as 15 minutes. Some men in clinical trials reported improved erections more than six hours after taking the drug. In clinical trials, 77% of men with general ED were able to get erections after taking Stendra, compared to 54% of men taking an inactive placebo pill. Among men with diabetes-related ED, 63% were able to get erections after taking the drug, compared to 42% of … Continue reading

Posted in Erectile Dysfunction | Comments Off on FDA Approves New Erectile Dysfunction Drug Stendra

Vivus Announces FDA Approval Of STENDRA™ (avanafil) Tablets For The Treatment Of Erectile Dysfunction

Posted: Published on April 29th, 2012

MOUNTAIN VIEW, Calif., April 27, 2012 /PRNewswire/ -- VIVUS, Inc. (VVUS) today announced that the U.S. Food and Drug Administration (FDA) has approved STENDRA (avanafil) tablets for the treatment of erectile dysfunction (ED), marking the first new prescription agent approved in nearly a decade for the condition that afflicts as many as 30 million men in the U.S. "Patients and treating physicians continue to report significant dissatisfaction with current treatments of ED," said Peter Tam, president, VIVUS. "We believe that the PDE5 selectivity and absorption profileof STENDRA make it an important new treatment option for many men with erectile dysfunction." More than 1,200 men with ED participated in clinical studies evaluating the efficacy and safety of STENDRA. STENDRA at all doses tested (50mg, 100mg and 200mg) met all primary efficacy endpoints. Significant improvement in erectile function was observed for all doses in STENDRA-treated patients compared to placebo. It is recommendedthat STENDRA should be taken approximately 30 minutes before sexual activity. STENDRA should not be taken more than once per day. For more information about STENDRA, please visit http://www.Stendra.com. "STENDRA is the first of a new generation of PDE5 inhibitors, and the approval marks an exciting new milestone for the millions … Continue reading

Posted in Erectile Dysfunction | Comments Off on Vivus Announces FDA Approval Of STENDRA™ (avanafil) Tablets For The Treatment Of Erectile Dysfunction

FDA approves new drug for erectile dysfunction

Posted: Published on April 29th, 2012

A medication that could be a faster-working alternative to Viagra and other erectile dysfunction drugs got approval from the Food and Drug Administration Friday. The brand name you will be hearing in those inevitable ads: Stendra. It's made by a company called Vivus, Inc., and belongs to the same class of medicines as Viagra, from Pfizer Inc., Cialis, from Eli Lilly, and Levitra, from GlaxoSmithKline and Bayer. All inhibit the same enzyme, PDE5, and work by increasing blood flow to the penis. About 30 million men have erectile dysfunction -- trouble getting or keeping an erection -- the FDA says. The approval "expands the available treatment options" for such men and "enables patients, in consultation with their doctor, to choose the most appropriate treatment," FDA official Victoria Kusiak said in a statement. The statement says patients will be instructed to take Stendra 30 minutes before sexual activity. But, in studies, the drug has been shown to work in as little as 15 minutes, which is faster than the 30 to 60 minutes reported for other drugs (though they have not been directly compared in studies). The new drug will come with the same warnings as the others: 2% of patients … Continue reading

Posted in Erectile Dysfunction | Comments Off on FDA approves new drug for erectile dysfunction

FDA approves new erectile dysfunction pill Stendra

Posted: Published on April 29th, 2012

The U.S. Food and Drug Administration approved a new erectile dysfunction drug, Stendra, on Friday. The pill's makers claim it works faster than Viagra. (EPA/ANTONIO LACERDA / April 27, 2012) April 27, 2012, 11:45 a.m. The U.S. Food and Drug Administrationapproved Stendra, a new drug to treat erectile dysfunction in men, on Friday. Like Viagra, Cialis and Levitra, Stendra (generic name avanafil) is a pill, and is in a class of drugs called PDE5 inhibitors.These work by increasing blood flow to the penis. Patientscan take Stendra as needed 30 minutes before sexual activity, the FDA said in a statement released Friday. One possible advantage of the new drug? Vivus Inc., the company that markets Stendra, has claimed that it will provide erections in 15 minutes or less in about half as much time as Viagra can. Like other PDE5 inhibitors, Stendra is not recommended for men who take nitrates for chest pain, because taking both drugs can cause a rapid drop in blood pressure, the FDA said.Side effects reported during clinical trials of Stendra included headache and cold-like symptoms. The National Kidney and Urologic Diseases Information Clearinghouse provides information about erectile dysfunction and its treatment at this website. See original … Continue reading

Posted in Erectile Dysfunction | Comments Off on FDA approves new erectile dysfunction pill Stendra

New drug approved for erectile dysfunction

Posted: Published on April 29th, 2012

MOUNTAIN VIEW, Calif., April 28 (UPI) -- The U.S. Food and Drug Administration has approved Stendra, or avanafil, tablets for the treatment of erectile dysfunction in men, officials said. Peter Tam, president of the biopharmaceutical company Vivus, said the approval is the first for nearly a decade to help treat the 30 million U.S. men with erectile dysfunction. "Patients and treating physicians continue to report significant dissatisfaction with current treatments of erectile dysfunction," Tam said in a statement. "We believe that the PDE5 selectivity and absorption profile of Stendra make it an important new treatment option for many men with erectile dysfunction." More than 1,200 men with erectile dysfunction participated in clinical studies evaluating the efficacy and safety of Stendra, and significant improvement in erectile function was observed for all doses -- in 50milligrams, 100mg and 200mg -- compared to placebo. It is recommended that Stendra should be taken approximately 30 minutes before sexual activity and should not be taken more than once per day. Erectile dysfunction affects an estimated 52 percent of men between the ages of 40 and 70, Tam said. Read the original here: New drug approved for erectile dysfunction … Continue reading

Posted in Erectile Dysfunction | Comments Off on New drug approved for erectile dysfunction

Stendra (Avanafil) For Erectile Dysfunction Approved By FDA

Posted: Published on April 29th, 2012

Editor's Choice Main Category: Erectile Dysfunction / Premature Ejaculation Also Included In: Urology / Nephrology;Regulatory Affairs / Drug Approvals Article Date: 28 Apr 2012 - 0:00 PDT email to a friend printer friendly opinions Current Article Ratings: 4.14 (7 votes) 2.5 (4 votes) Stendra is a medication that is taken, when needed, 30 minutes before starting sexual activity. Doctors are advised to prescribe the lowest dose at which benefit is provided for the patients. Victoria Kusiak, M.D., deputy director of the Office of Drug Evaluation III in the FDA's Center for Drug Evaluation and Research, said: Stendra is a PDE5 (phosphodiesterase type 5) inhibitor, and increases blood flow to the penis. Patients taking nitrates should not be given this medication, the FDA emphasizes. Nitrates are often used to treat angina - combining Stendra with nitrates can bring about a sudden and severe drop in blood pressure. In very rare cases, patients taking PDE5 inhibitors may experience color vision changes. On rarer occasions, patients may report sudden vision loss in one eye (and sometimes both). Some patients have reported loss of hearing, or decreased hearing. If you experience a sudden loss of hearing or vision you should cease taking any kind … Continue reading

Posted in Premature Ejaculation | Comments Off on Stendra (Avanafil) For Erectile Dysfunction Approved By FDA

College Kids Often Use Cell Phones While Driving: Study

Posted: Published on April 29th, 2012

THURSDAY, April 26 (HealthDay News) -- Distracted driving due to texting and use of other electronic devices is common among college students in California, according to a new study. Previous research has shown that using cell phones while driving increases the risk of crashes fourfold, and that handheld and hands-free phones are equally dangerous. The risk of crashing while texting is eight to 16 times higher than normal. The new study included nearly 5,000 students, average age 21, from the University of California, San Diego (UCSD); San Diego State University; the University of San Diego; California State, San Marcos; and eight smaller colleges in the region. The researchers found that 78 percent of the students reported using a cell phone to talk or text while driving, 52 percent said they used hands-free devices while driving at least some of the time, 47 percent used hands-free devices at least half of the time while driving and 25 percent frequently used hands-free devices. Half of the students said they send texts while driving on the freeway, 60 percent send texts while in stop-and-go traffic or when driving on city streets, and 87 percent send texts while at traffic lights. Only 12 percent … Continue reading

Posted in Cell Medicine | Comments Off on College Kids Often Use Cell Phones While Driving: Study

Drop off old prescriptions for National Prescription Take Back Day

Posted: Published on April 29th, 2012

SAN DIEGO (CNS) - People with expired or unneeded prescription drugs can get rid of them safely Saturday by participating in the U.S. Drug Enforcement Administration's fourth National Prescription Take Back Day. Law enforcement agencies, military bases, hospitals, universities and businesses across the county will accept dropped-off medications between 10 a.m. and 2 p.m., according to the DEA. The service is free and anonymous, with no questions asked. "Getting these potentially harmful drugs off the streets of our community is an important step in decreasing prescription-drug abuse among our youth," said William Sherman, acting special agent in charge of the DEA's San Diego office. During the most recent Prescription Take Back Day, in September, authorities collected 7,113 pounds of medications from San Diego and Imperial counties. Nationally, a total of over 188.5 tons of medications was turned in at 5,327 drop-off sites. Misuse of prescription drugs is a growing problem in the United States, according to medical and law enforcement officials. The substances often fall into the hands of recreational users -- many of them minors raiding their parents' medicine cabinets -- or are improperly discarded, posing public-health risks. A 2009 national survey by the Substance Abuse and Mental Health … Continue reading

Posted in Prescriptions | Comments Off on Drop off old prescriptions for National Prescription Take Back Day

Gilenya Heart Side Effects – European Medicine Agency Gives New Recommendations

Posted: Published on April 29th, 2012

Editor's Choice Main Category: Cardiovascular / Cardiology Also Included In: Multiple Sclerosis Article Date: 27 Apr 2012 - 13:00 PDT email to a friend printer friendly opinions Current Article Ratings: 2 (1 votes) The Agency's Committee for Medicinal Products for Human Use (CHMP) recommends that patients' that are deemed necessary to receive Gilenya should have their heart activity monitored for a minimum of one night after taking the first dose of Gilenya, and that doctors should seek advice on appropriate monitoring from a cardiologist. The new recommendations also include that all patients who start Gilenya therapy should have their heart activity monitored prior to taking the first dose and continuously for a minimum of six hours afterwards, whilst those whose heart rate is lowest six hours after receiving the first dose should be monitored for at least two hours extra. Patients developing considerable clinical heart problems like bradycardia (low heart rate) or atrioventricular (AV) block, a conductivity problem in the heart, should be monitored at least overnight and until the problems have been resolved. Since March 2011, Gilenya, the first disease-modifying MS treatment available as an oral formulation, has been authorized in the EU to treat relapsing-remitting MS in patients … Continue reading

Posted in Drug Side Effects | Comments Off on Gilenya Heart Side Effects – European Medicine Agency Gives New Recommendations

Marketsensus: Overcoming Side-Effects Means the Difference Between Profit and Loss for Drug Companies

Posted: Published on April 29th, 2012

Drugs targeting the incretin system such as dipeptidyl peptidase-IV (DPP-IV) inhibitors are likely to account for the biggest share of the growing market due to their high safety and efficacy profiles. Incretin mimetics Glucagon-like-1 (GLP-1) agonists will also be able to garner a significant share of the diabetes market. New York, NY (PRWEB) April 24, 2012 According to new research available from Marketsensus, there are a number of molecules currently in development for the treatment of diabetes. The annually increasing prevalence and incidence of diabetes will be the key driving factors for the growth in the value of the diabetes market over the next few years. Research shows that products currently in the market do not serve the unmet need that exists in terms of safety and patient compliance and so the market continues to present opportunities for stronger pipeline candidates. However, for a company to capture this unmet need, it will need to overcome prevailing product weaknesses and adverse effects. These are the biggest challenges currently hindering most pipeline products. Drugs targeting the incretin system such as dipeptidyl peptidase-IV (DPP-IV) inhibitors are likely to account for the biggest share of the growing market due to their high safety and … Continue reading

Posted in Drug Side Effects | Comments Off on Marketsensus: Overcoming Side-Effects Means the Difference Between Profit and Loss for Drug Companies

Page 6,905«..1020..6,9046,9056,9066,907..6,9106,920..»